Pharmaceutical company Eli Lilly plans to acquire Morphic, a biopharmaceutical company that specializes in treating gastroenterology patients, for $3.2 billion.
Eli Lilly strengthens GI focus through $3.2B acquisition
Pharmaceutical company Eli Lilly plans to acquire Morphic, a biopharmaceutical company that specializes in treating gastroenterology patients, for $3.2 billion.